Literature DB >> 16485918

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

David J Back, Andrew Owen, Saye H Khoo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16485918     DOI： 10.2165/00003088-200645020-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  13 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.

Authors:  Stéphane Mouly; Kenneth S Lown; David Kornhauser; Jeffrey L Joseph; William D Fiske; Irma H Benedek; Paul B Watkins
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

3.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

4.  Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

Authors:  Sonia Rodriguez-Novoa; Pablo Barreiro; Ana Rendón; Inmaculada Jiménez-Nacher; Juan González-Lahoz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2005-03-31       Impact factor: 9.079

5.  The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.

Authors:  Carlos Alonso-Villaverde; Blai Coll; Federico Gómez; Sandra Parra; Jordi Camps; Jorge Joven; Lluis Masana
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

6.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.

Authors:  Margalida Rotger; Sara Colombo; Hansjakob Furrer; Gabriela Bleiber; Thierry Buclin; Belle L Lee; Olivia Keiser; Jérôme Biollaz; Laurent Décosterd; Amalio Telenti
Journal:  Pharmacogenet Genomics       Date:  2005-01       Impact factor: 2.089

7.  Efavirenz intoxication due to slow hepatic metabolism.

Authors:  B Hasse; H F Günthard; G Bleiber; M Krause
Journal:  Clin Infect Dis       Date:  2005-01-07       Impact factor: 9.079

8.  Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.

Authors:  Bregt S Kappelhoff; Alwin D R Huitema; Zeynep Yalvaç; Jan M Prins; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

9.  Are adverse events of nevirapine and efavirenz related to plasma concentrations?

Authors:  Bregt S Kappelhoff; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Ezio Baraldi; Francesco Montella; David E Uip; Melanie A Thompson; Darren B Russell; Joep M A Lange; Jos H Beijnen; Alwin D R Huitema
Journal:  Antivir Ther       Date:  2005

10.  No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.

Authors:  Ralf Winzer; P Langmann; M Zilly; F Tollmann; J Schubert; H Klinker; B Weissbrich
Journal:  Eur J Med Res       Date:  2003-12-09       Impact factor: 2.175
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.